Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 11/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.65 |
| ▸ | KDR | P35968 | 10/20 | 0.65 |
| ▸ | JAK3 | P52333 | 5/20 | 0.65 |
| ▸ | TEK | Q02763 | 5/20 | 0.65 |
| ▸ | BRAF | P15056 | 3/20 | 0.60 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.58 |
| ▸ | KIT | P10721 | 6/20 | 0.56 |
| ▸ | RAF1 | P04049 | 2/20 | 0.54 |
| ▸ | SRC | P12931 | 2/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | BCR | P11274 | 1/20 | 0.53 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10159643 | 0.85 | TRPV1 (0.48) | LCKMAPK14KDRJAK3TEK | |
| SCHEMBL13219723 | 0.83 | LCK (0.76) | LCKMAPK14KDRJAK3TEK | |
| SCHEMBL13220068 | 0.82 | KDR (0.74) | LCKMAPK14KDRJAK3TEK | |
| SCHEMBL13220047 | 0.82 | KDR (0.69) | LCKMAPK14KDRJAK3TEK | |
| SCHEMBL1704008 | 0.82 | MAPK14 (0.44) | LCKMAPK14KDRJAK3TEK | |
| SCHEMBL1704882 | 0.80 | MAPK14 (0.68) | LCKMAPK14KDRBRAFRAF1 | |
| SCHEMBL1704606 | 0.80 | ABL1 (0.49) | MAPK14RAF1ABL1CSF1RMAPT | |
| SCHEMBL13220176 | 0.80 | MAPK14 (0.62) | LCKMAPK14KDRJAK3TEK | |
| SCHEMBL5491324 | 0.79 | KDR (0.65) | LCKMAPK14KDRJAK3TEK | |
| SCHEMBL19328015 | 0.79 | CSF1R (0.63) | LCKMAPK14KDRJAK3TEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505784-B2 | Fused 2-aminothiazole compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150094315-A1 | FUSED 2-AMINOTHIAZOLE COMPOUNDS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-8765747-B2 | Fused 2-aminothiazole compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120088766-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| WO-2010144909-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088766-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USES | OAT, OTC, DLD | LCK 1107/4885MAPK14 4759/4885KDR 1877/4885 |
| US-20150094315-A1 | FUSED 2-AMINOTHIAZOLE COMPOUNDS | GOT2, OAT, ABAT | LCK 290/4885MAPK14 4735/4885KDR 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.